Stocks · News reference
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 12:40 PM
- Checked
- Jul 24, 2026, 12:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
Read original at benzingaGreenland Mines Outlines $2B Valuation for Sarfartoq Project
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.
Read original at benzingaNeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Read original at benzinga